Skip to main content
Signal8
Launch Terminal

CURIS INC (CRIS)

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Curis, Inc. logo

Curis, Inc.

NASDAQ:CRISHealthcare
+9.39%$0.6000
AH$0.5565-7.25%vs close
Mkt Cap$4.01M
Float6.66M
O/S6.68M
Vol
$ Vol
RVOL
Inst Own10.1%
Earnings
Dilution
Curis, Inc. logoNASDAQ:CRIS$0.6000+9.39%
Phase Distribution
13 lead-sponsored trials·2 active·8 completed
Phase 19
Phase 1/22
Phase 22
(6 more as collaborator)
Status Overview
Recruiting2
Completed8
Stopped3

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2
    Completed

    Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations

    CUDC-907

    Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations

    Enrollment
    70
    Start
    Jul 2016
    Primary Completion
    May 2019
    Completion
    May 2019
    NCT02674750
  • Phase 2
    Recruiting

    A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

    Emavusertib, Zanubrutinib

    Chronic Lymphocytic Leukemia, B-cell Malignancies

    Enrollment
    108
    Start
    Apr 2026
    Primary Completion
    Nov 2027est.
    Completion
    Nov 2027est.
    NCT07271667
  • Phase 1/2
    Recruiting

    CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

    Emavusertib, Ibrutinib

    Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy +2

    Enrollment
    152
    Start
    Dec 2017
    Primary Completion
    Jul 2027est.
    Completion
    Oct 2027est.
    NCT03328078
  • Phase 1/2
    Suspended

    Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

    Emavusertib, Venetoclax

    Acute Myelogenous Leukemia, Myelodysplastic Syndrome

    Enrollment
    366
    Start
    Jul 2020
    Primary Completion
    Apr 2026est.
    Completion
    Apr 2026est.
    NCT04278768
  • Phase 1
    Completed

    A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors

    CUDC-101

    Tumors

    Enrollment
    25
    Start
    Aug 2008
    Primary Completion
    Apr 2010
    Completion
    Apr 2010
    NCT00728793
  • Phase 1
    Completed

    A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors

    CUDC-101, CUDC-101

    Head and Neck Cancer, Liver Cancer +3

    Enrollment
    47
    Start
    Jul 2010
    Primary Completion
    Oct 2011
    Completion
    Oct 2011
    NCT01171924
  • Phase 1
    Completed

    Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer

    CUDC-101, Cisplatin

    Head and Neck Cancer

    Enrollment
    12
    Start
    Nov 2011
    Primary Completion
    Sep 2013
    Completion
    Oct 2013
    NCT01384799
  • Phase 1
    Terminated

    Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients

    CUDC-101

    Cancer

    Enrollment
    3
    Start
    Sep 2012
    Primary Completion
    Dec 2012
    Completion
    Dec 2012
    NCT01702285
  • Phase 1
    Completed

    Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

    fimepinostat, Rituximab

    Lymphoma, Relapsed Lymphoma +9

    Enrollment
    106
    Start
    Dec 2012
    Primary Completion
    Oct 2020
    Completion
    Oct 2020
    NCT01742988
  • Phase 1
    Terminated

    Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma

    CUDC-427

    Lymphoma

    Enrollment
    23
    Start
    Jul 2013
    Primary Completion
    Mar 2015
    Completion
    Nov 2015
    NCT01908413
  • Phase 1
    Completed

    Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

    CUDC-907

    Triple-Negative Breast Cancer, High-grade Serous Ovarian Cancer +2

    Enrollment
    43
    Start
    Nov 2014
    Primary Completion
    May 2019
    Completion
    May 2019
    NCT02307240
  • Phase 1
    Completed

    A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

    CA-170

    Advanced Solid Tumors or Lymphomas

    Enrollment
    71
    Start
    May 2016
    Primary Completion
    May 2020
    Completion
    May 2020
    NCT02812875
  • Phase 1
    Completed

    Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies

    CI-8993

    Solid Tumor

    Enrollment
    26
    Start
    Sep 2020
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT04475523
Search ClinicalTrials.gov for “Curis”